Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141661 · ClinicalTrials.gov registry record · Phase 2
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00141661 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 67 participants.
The verdict
NCT00141661, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
Interventions
- DRUG Placebo Comparator
- DRUG PF-04494700 - Low Dose Arm
- DRUG PF-04494700 - High Dose Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141661
The ClinicalTrials.gov registry entry for NCT00141661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT00141661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141661 about?
NCT00141661 is a clinical study titled "A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients". A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
What is the current status of trial NCT00141661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00141661?
The interventions under investigation include: Placebo Comparator (DRUG), PF-04494700 - Low Dose Arm (DRUG), PF-04494700 - High Dose Arm (DRUG).
Who is sponsoring clinical trial NCT00141661?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.